Nektar Therapeutics Q3 Earnings Boost Analysts' Bullish Outlook

Nektar Therapeutics' Q3 results exceeded expectations, with revenues of $12m beating estimates by 16%. Statutory losses were $1.87, 28% smaller than expected. Analysts revised their forecasts, with revenues expected to be $40m in 2026, a 36% reduction from the previous year. Losses are forecast to balloon 53% to $9.70 per share. The consensus price target rose 8.7% to $105.